Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Iannitto

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Clinical Lymphoma & Myeloma|May 2, 2009
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trialEmilio Iannitto, Viviana Minardi, Paolo G Gobbi, et al.
Haematologica|April 6, 2006
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's diseaseAndrea Gallamini, Luigi Rigacci, Francesco Merli, et al.
Annals of Hematology|February 22, 2012
Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL)Luigi Rigacci, Benedetta Puccini, Sergio Cortelazzo, et al.
Leukemia & Lymphoma|June 27, 2013
Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical useCarlos Montalban, Victor Abraira, Luca Arcaini, et al.
British Journal of Haematology|August 29, 2012
Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 casesCarlos Montalbán, Víctor Abraira, Luca Arcaini, et al.
British Journal of Haematology|March 5, 2011
Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective studyEmilio Iannitto, Fortunato Morabito, Salvatrice Mancuso, et al.
Blood|January 24, 2014
Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphomaGiovanni Franco, Carla Guarnotta, Barbara Frossi, et al.
Cancer Medicine|July 26, 2020
Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trialsMarc P E André, Patrice Carde, Simonetta Viviani, et al.
International Journal of Hematology|November 27, 2008
Advanced mast cell disease: an Italian Hematological Multicenter experienceLivio Pagano, Caterina Giovanna Valentini, Morena Caira, et al.
Blood|February 24, 2006
Splenic marginal zone lymphoma: a prognostic model for clinical useLuca Arcaini, Mario Lazzarino, Nora Colombo, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Clinical Lymphoma & Myeloma|May 2, 2009
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trialEmilio Iannitto, Viviana Minardi, Paolo G Gobbi, et al.
Haematologica|April 6, 2006
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's diseaseAndrea Gallamini, Luigi Rigacci, Francesco Merli, et al.
Annals of Hematology|February 22, 2012
Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL)Luigi Rigacci, Benedetta Puccini, Sergio Cortelazzo, et al.
Leukemia & Lymphoma|June 27, 2013
Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical useCarlos Montalban, Victor Abraira, Luca Arcaini, et al.
British Journal of Haematology|August 29, 2012
Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 casesCarlos Montalbán, Víctor Abraira, Luca Arcaini, et al.
British Journal of Haematology|March 5, 2011
Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective studyEmilio Iannitto, Fortunato Morabito, Salvatrice Mancuso, et al.
Blood|January 24, 2014
Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphomaGiovanni Franco, Carla Guarnotta, Barbara Frossi, et al.
Cancer Medicine|July 26, 2020
Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trialsMarc P E André, Patrice Carde, Simonetta Viviani, et al.
International Journal of Hematology|November 27, 2008
Advanced mast cell disease: an Italian Hematological Multicenter experienceLivio Pagano, Caterina Giovanna Valentini, Morena Caira, et al.
Blood|February 24, 2006
Splenic marginal zone lymphoma: a prognostic model for clinical useLuca Arcaini, Mario Lazzarino, Nora Colombo, et al.
Pageof 7